Hybrigenics hires head of corporate and business development

William Vickery joins firm from ExonHit

Hybrigenics, a French bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialised in protein interactions services, has appointed William Vickery to the newly created position of head of corporate and business development.

Vickery was for five years senior director of business development at ExonHit.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, he was business development director of Roche Pharmaceuticals in the US, where he was responsible for out-licensing and divestiture of Roche-developed assets.

‘I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,’ said Vickery.

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas
Ingredients

Hybrigenics develops new oral formulations of inecalcitol

New capsules are more concentrated in inecalcitol and contain a fixed 2mg amount that will be more convenient, with a maximum of two small capsules to swallow, which also favours compliance
Ingredients

Hybrigenics improves inecalcitol synthesis

French firm makes patent application for high-yield inecalcitol production
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Subscribe now